Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (10886)	8/18/2018 8:48:31 AM
From: donpat	Read Replies (1) \| Respond to of 12873

A license depends on many things, usually how much money it can generate. I've seen licenses from 1% to double figures, usually 2% - 3%. If $billions will be involved 3% is pretty good, if less $s, then a higher % is OK, but one needs to know how valuable the license is. I do not think that is known at this time. What do you think? The licensing terms matter but it is something to consider when the FDA approves the drug - because that approval if not forthcoming changes the value immensely and vice versa. It's kinda like easy street vs the gutter. Now try and put a negative perspective on that! lol